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ABSTRACT
We present a comparative analysis of clinical presentation and response to treatment in 170 patients with
chronic graft versus host disease (cGVHD) (123 following transplant from an unrelated donor [URD] and 47
from umbilical cord blood [UCB]). URD transplant recipients were significantly younger (median age 25 versus
39 years, P  .002; and the donor grafts were mostly HLA matched (67% versus 10%, P < .0001). UCB
recipients had more frequent responses (complete remission [CR]  partial remission [PR]) to treatment
(URD 48% versus UCB 74% at 2 months [P  .005]; 49% versus 78% at 6 months [P  .001] and 51% versus
72% at 1 year [P  .03] in the URD and UCB groups, respectively). Nonrelapse mortality (NRM) after
diagnosis of cGVHD was worse after URD grafts. (1 year NRM 27% [19%-35%] URD versus 11% [2%-20%]
UCB, P .055). Separate multivariate analyses were performed in each cohort. In both, thrombocytopenia and
no CR or PR at 2 months were independently associated with increased mortality. In addition, progressive
onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that
cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a
ajor cause of morbidity and mortality after alloge-
eic hematopoietic stem cell transplant (HSCT).
arge observational studies have shown that cGVHD
s the leading cause of nonrelapse mortality (NRM) 2
ears after transplantation [1]. Many factors are asso-
iated with higher risks of cGVHD. These include
lder age, certain diagnoses (chronic myelogenous
eukemia (CML) and aplastic anemia), history of prior
cute GVHD (aGVHD), an HLA mismatched donor,
nd transplant from a parous female donor to a male ecipient [2-8]. Use of peripheral blood stem cells
PBSC) compared to bone marrow from related or
nrelated donors (URD) as a source of hematopoietic
tem cells (HSC) has also resulted in a higher fre-
uency of cGVHD [9-14]. In addition, risk factors
ave been identiﬁed that suggest worse outcome with
GVHD treatment. These are “extensive” cGVHD
5-17] (multiorgan or extensive cutaneous involve-
ent), poor Karnofsky performance status [15] pres-
nce of thrombocytopenia (100,000 cells/L)
15,16,18,19], progressive-type onset [16,18,20], li-
henoid histology [24], elevated bilirubin [20], age
20 years [18], gastrointestinal involvement [18], ab-
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M. Arora et al.1146ence of response to therapy at 6 months [18], and
ther subjective measures of severity [21].
The use of umbilical cord blood transplants
UCB) as a stem cell source for transplants has dra-
atically increased over the past decade. Although
egistry reports indicate that UCB is associated with a
educed incidence of extensive cGVHD [22,23], there
as been no detailed analysis of cGVHD in terms of
reatment responsiveness and associated risk factors.
herefore, we evaluated the incidence, clinical pre-
entation, response to treatment, and outcome of
GVHD in recipients of UCB with comparison to
esults in recipients of adult volunteer URD HSCT.
ATIENTS AND METHODS
ligibility Criteria
Patients who underwent HLA matched or mis-
atched volunteer adult URD or unrelated UCB
SCT at the University of Minnesota between May
993 and June 2004 were evaluated, and all consecu-
ive patients who developed cGVHD were included in
he study. The cohort includes 170 patients with
ymptomatic cGVHD (123 following URD and 47
fter UCB transplants). The diagnosis of cGVHD was
ade according to standard clinical and/or histologic
riteria [2,18,24]. For all patients, HLA-A and -B
yping was determined at the serologic level, whereas
LA-DRB1 allele level typing was determined by
igh-resolution molecular techniques.
reatment Plan of cGVHD
Limited skin involvement was treated with topical
teroids (0.1% triamcinolone cream to body, 1% hy-
rocortisone cream to face) 3 times a day. Most pa-
ients were treated with a combination of prednisone
t a dose of 0.5 mg/kg/every other day  calcineurin
nhibitor (n  153), along with initial therapy with
igh dose methylprednisone at a dose of 15 mg/kg as
n i.v. injection given weekly for 8 weeks (n  92: 79
ollowing URD and 13 following UCB). Additional
herapy included azathioprine in 6 patients (URD)
nd mycophenolate mofetil (MMF) in 11 patients (5
RD, 6 UCB). Salvage therapy was required in 51
atients (38 URD, 13 UCB) and included pulse
ethyprednisolone (15 mg/kg/day i.v. for 5 days) in 4
RD, 1 UCB recipient. Twenty-eight patients re-
eived MMF (17 URD, 11 UCB), 8 received thalido-
ide (all URD), and 10 received antithymocyte glob-
lin (ATG; 9 URD, 1 UCB). Treatment was
ontinued for 6-9 months following the last clinical
igns or symptoms of active cGVHD followed by a
aper over 3 months.
easurement of Response
Response was assessed at 2 months, 6 months, 1
ear, and 2 years after diagnosis of cGVHD. Because datients did not always return to the transplant center
n the scheduled dates, 2-4 month window periods
ere used to maximize the completeness of evaluation.
fter diagnosis of cGVHD, the median follow-up of
urviving patients was 5 years (range 0.5-10.8 years) in
he URD group and 1.5 years (range 0.4-8.8 years) in
he UCB group.
Complete response (CR) was deﬁned as resolution
f all reversible signs and symptoms of cGVHD. Par-
ial response (PR) was deﬁned as improvement in 1 or
ore organs of involvement and no evidence of wors-
ning in any organ. Progression was deﬁned as wors-
ning in 1 or more organs of involvement to be more
evere than at baseline. Flare included patients with
R or CR followed by worsening of cGVHD, which
as less severe than at the baseline evaluation. No
esponse (NR) included patients not meeting criteria
or PR or progression. Improvement or worsening of
isease was determined through both subjective and
bjective criteria. Subjective criteria were symptom-
tic change in cough, dyspnea, anorexia, nausea, vom-
ting, diarrhea, arthralgia, or dry eyes. Objective cri-
eria included physical exam of skin, oral mucosa,
eight change, and/or liver function tests, pulmonary
unction tests, Schirmer’s test, biopsies, and radiologic
tudies. All patients who died of complications related
o cGVHD (infections, multiorgan dysfunction) were
onsidered as nonresponders, regardless of cGVHD
ymptoms premortem. Responses were assigned ret-
ospectively by review of all medical records and lab-
ratory data.
tatistical Analysis
The study was a retrospective cohort study using
ata from the University of Minnesota HSCT data-
ase, which includes demographic data, type of onset
f cGVHD, dates of diagnosis of cGVHD and treat-
ent, organ involvement with cGVHD at diagnosis,
omplications, and causes of death/relapse. Data col-
ection and entry is carried out by trained personnel.
his was supplemented by chart reviews for speciﬁc
rgan involvement with cGVHD at deﬁned follow-up
eriods, response assessment, complications, and con-
inuation of therapy. Grading of response was per-
ormed without knowledge of the subsequent survival.
tatistical analysis of response was performed before
nalysis of survival to maintain objectivity.
Response to therapy. Response to therapy was eval-
ated serially. Patients with disease recurrence or pro-
ression were subsequently excluded from response
valuation. Of the 170 patients identiﬁed with
GVHD, the number of patients evaluable for re-
ponse was 168, 159, 151, and 148 at 2 months, 6
onths, 1 year, and 2 years, respectively. Twenty-two
13%) patients relapsed (16 URD, 6 UCB group) and
ied within 2 years without complete assessment of
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cGVHD Following URD and UCB Transplant 1147esponse. Of these, 2 had relapsed by 2 months, 11
elapsed by 6 months, 19 relapsed by 1 year, and 22 by
years. Twenty-seven, 8, 14, and 25 patients were
nly observed outside the deﬁned window periods or
ad inadequate information for evaluation at 2
onths, 6 months, 1 year, and 2 years, respectively.
earson’s chi-square test was employed to compare
he proportion of subjects with response to therapy
etween the 2 groups.
Predictors of response. Ten potential predictors
ere evaluated, including recipient age at transplant
30 versus 30 years), gender of recipient and
onor (female donor and male recipient versus oth-
rs), type of transplant (URD versus UCB ), HLA
ismatch (0 or 1 versus 1), conditioning regimen
myeloablative versus nonmyeloablative), GVHD
rophylaxis (T cell depletion versus others), prior
rade II-IV aGVHD, type of onset of cGVHD
de novo  quiescent versus progressive), organ
nvolvement with cGVHD (eyes, mouth, skin,
ungs, gastrointestinal, liver) and platelet count at
resentation (100,000/L versus 100,000/L).
earson’s chi-square test was employed to compare
he proportion of subjects with response to therapy
ithin each category of potential predictors. Multivar-
ate logistic regression was used to evaluate the inde-
endent effect of study variables on treatment re-
ponse. A stepwise regression with forward selection
as used.
Survival. Patient survival was determined using
he Kaplan-Meier [25] estimation with 95% conﬁ-
ence intervals (CI) derived from standard errors. Pa-
ients were censored at the date of last contact. Sur-
ival was estimated from onset of cGVHD.
Predictors of mortality. Potential factors associated
ith mortality were studied. The Kaplan-Meier prod-
ct limit method [25] and log rank testing were used
o compare survival in the subsets and the Cox regres-
ion model [26] was used to assess the independent
ffect of the predictors on survival as well as any
otential confounding on the effect of treatment. A
tepwise regression with forward selection was used.
umulative incidence rates were used to estimate the
robability of relapse, NRM, and discontinuation of
ll immunosuppressive treatment [27] over the com-
lete period of follow-up.
ESULTS
The overall incidence of cGVHD was 25% (21%-
9%) and 17% (13%-21%) in patients undergoing
RD and UCB transplants, respectively. Table 1
hows the characteristics of the patients developing
GVHD. The median age at transplantation was 25
nd 39 years in the URD and UCB groups, respec-
ively. URD recipients were more likely to receive syeloablative conditioning (93% versus 57%) and to
eceive an HLA matched graft (67% versus 10%).
here was no difference in the time to onset (186 days
ersus 178 days), type of onset, or distribution of
rgan involvement by cGVHD comparing URD and
CB groups. Skin was the most frequent organ in-
olved (64% versus 53%), followed by oral (44% vs
5%) and gastrointestinal tract (29% versus 34%).
igh-risk disease (as deﬁned by progressive onset and
hrombocytopenia) was seen in 76 patients (45%)
verall. Of these, progressive onset was seen in 33
27%) patients in the URD cohort versus 9 (19%) in
he UCB cohort (P  .15). Thrombocytopenia (plate-
et count 100,000/L) was seen more frequently in
he URD cohort (44 (54%) versus 7 (23%), P  .003).
esponse to Therapy
Response was assessed serially at 2 months, 6
onths, 1 year, and 2 years in all patients (Tables 2
nd 3). Overall response rates (CR PR) to treatment
ere higher in UCB recipients at all time points.
imilar rates of CR were attained in both groups. The
peed of attainment of CR, however, was faster in the
CB group.
The response rates (CR  PR) were URD 48%
ersus UCB 74% at 2 months (P  .005), 49% versus
8% at 6 months (P  .001), 51% versus 72% at 1
ear (P  .03), and 47% versus 70% (P  .05) at 2
ears, respectively. The CR rates were 19% versus
8% at 2 months (P  .01), 31% versus 34% at 6
onths (P  .7), 38% versus 38% at 1 year (P  .9),
nd 40% versus 52% (P  .3) at 2 years.
redictors of Response
We analyzed 10 clinical factors as potential pre-
ictors of early (at 2 months) and late response (at 2
ears). In univariate analysis, early and late responses
ere more frequent in patients with de novo/quies-
ent onset of cGVHD (64% versus 33%, P  .0006 at
months, 66% versus 31%, P  .0004 at 2 years),
latelet count of100,000/L (64% versus 41%, P
03 at 2 months, 64% versus 40%, P  .03 at 2 years),
CB transplant (74% versus 48%, P  .005 at 2
onths, 70% versus 47%, P  .05 at 2 years), and in
atients without liver involvement (58% versus 31%,
 .05 at 2 years). In multivariate analysis, de novo/
uiescent onset of disease (OR 3.2, P  .03) and UCB
ransplant (odds ratio [OR] 3.8, P  .02) remained
mportant predictors of more frequent early (2
onths) and late responses (Tables 4 and 5). Myeloa-
lative (versus nonmyeloablative) conditioning (P 
3) and recipient age30 years (versus30 years) had
imilar response rates (P  .3).
TN
D
A
D
T
C
H
C
G
a
O
T
O
T
F
U
M. Arora et al.1148able 1. Demographics and Disease Characteristics
Demographics URD No. (%) UCB No. (%) P
123 47
iagnosis
Acute leukemia 38 (31) 25 (53) <.001
CML 36 (29) 4 (9)
Nonmalignant diseases 43 (35) 9 (19)
Other malignancies 6 (5) 9 (19)
ge
Median (range) 25 (0.5-57) 39 (0.2-61) .002
<20 years 55 (45) 16 (34) .003
21-40 years 40 (33) 8 (17)
>40 years 28 (23) 23 (49)
onor /recipient sex mismatch
Male recipient with Female donor 34 (28) 12 (26)
ype of conditioning
Myeloablative 114 (93) 27 (57) <.0001
Nonmyeloablative 9 (7) 20 (43)
ell source
Marrow 121 (98)
PBSC 2 (2)
UCB 47 (100%)
LA match
6/6 82 (67) 5 (10) <.0001
5/6 38 (31) 13 (28)
4/6 3 (2) 29 (62)
onditioning regimens
TBI  cyclophosphamide 77 (63) 10 (21) <.0001
Busulfan  cyclophosphamide  other 10 (8) 3 (6)
Fludarabine  TBI  Cyclophosphamide/busulfan 11 (9) 29 (62)
Other 25 (20) 5 (11)
VHD prophylaxis
Methotrexate  CSA 65 (53) 0 <.0001
T depletion 40 (33) 0
CSA  Prednisone 0 16 (34)
CSA  MMF 9 (7) 30 (64)
Other 9 (7) 1(2)
GVHD
None 29 (24) 7 (15) .17
Grade I-II 74 (60) 27 (57)
Grade III-IV 20 (16) 13 (28)
nset of cGVHD
De novo 29 (23) 7 (15) .15
Quiescent 61 (50) 31 (66)
Progressive 33 (27) 9 (19)
ime to cGVHD
(days post transplant):median (range) 186 (73-886) 178 (75-505) .67
rgan involvement with cGVHD
Skin 79 (64) 25 (53) .18
Oral 54 (44) 21 (45) .9
Liver 17 (14) 4 (9) .34
GI 36 (29) 16 (34) .5
Lungs 7 (6) 1 (2) .3
Eyes 19 (15) 7 (15) .9
hrombocytopenia
N (%) with platelet count <100,000/L at onset of
cGVHD (n  111) 44 (54) (n  81) 7 (23) (n  30) .003
ollow-up [median (range), years] 5 (0.14-10.8) 1.5 (0.02-8.8)
RD indicates unrelated donor; UCB, umbilical cord blood; CML, chronic myelogenous leukemia; TBI, total body irradiation; GVHD,
graft-versus-host disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HLA, human leukocyte
antigen; PBSC, perpipheral blood stem cells; CSA, cyclosporine; MMF, mycophenolate mofetil; GI, gastrointestional.
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cGVHD Following URD and UCB Transplant 1149urvival
Overall survival (OS) after onset of cGVHD was
9% (50%-67%) in URD versus 71% (53%-83%) in
CB recipients at 2 years and 54% (44%-63%) versus
4% (42%-79%) (P  .1) at 4 years (Figure 1Ai).
early all deaths (85%) occurred within 2 years of
GVHD diagnosis, and most (n  45, 63%) died of
omplications related to cGVHD. Two patients (3%)
ied of a second malignancy and 1 patient (1.4%) died
f complications unrelated to HSCT. Twenty-three
atients (32%) relapsed (22 within 2 years of cGVHD)
nd died. Eleven late deaths (beyond 2 years from
iagnosis) occurred. Of these, 8 patients died of com-
lications related to cGVHD, 1 of a second malig-
ancy, 1 relapsed, and 1 died of other complications.
he disease-free survival (DFS) was 55% (46%-63%)
n URD versus 71% (55%-82%) in UCB at 2 years
nd 51% (41%-60%) versus 55% (30%-74%) at 4
ears, P  .4 (Figure 1Aii).
elapse and NRM
The cumulative incidence of relapse was similar in
he 2 groups (12% [6%-18% in URD versus 18%
8%-28%] in UCB), P  .3 (Figure 1Bi).
Higher NRM after cGVHD was seen in recipients
f URD transplant. The NRM was 13% (95% CI
%-19%) versus 7% (95%CI 1%-13%) at 3 months
able 2. Frequency of Early Response
2 Months N (%)
Evaluable  168
6 months N (%)
Evaluable  159
Response URD UCB P URD UCB P
102 39 110 41
R 19 (19) 15 (38) .014 34 (31) 14 (34) .004
R 30 (29) 14 (36) 20 (18) 18 (44)
D 42 (41) 6 (15) 46 (42) 6 (15)
lare — — 9 (8) 2 (5)
rogression 11 (11) 4 (10) 1 (1) 1 (1)
RPR 49 (48) 29 (74) .005 54 (49) 32 (78) .001
DFlare 53 (52) 10 (26) 56 (51) 9 (22)
R indicates complete response; PR, partial response; SD, stable
disease; URD, unrelated donor; UCB umbilical cord blood.
able 3. Frequency of Late Response
1 Year N (%)
Evaluable  151
2 Years N (%)
Evaluable  148
Response URD UCB P URD UCB P
105 32 100 23
R 40 (38) 12 (38) .02 40 (40) 12 (52) .13
R 13 (12) 11 (34) 7 (7) 4 (17)
D 41 (39) 6 (19) 46 (46) 5 (22)
lare 11 (11) 3 (9) 7 (7) 2 (9)
RPR 53 (51) 23 (72) .03 47 (47) 16 (70) .05
DFlare 52 (49) 9 (28) 53 (53) 7 (30)
R indicates complete response; PR, partial response; SD, stable
disease; URD, unrelated donor; UCB umbilical cord blood.nd 27% (95% CI 19%-35%) versus 11% (95% CI
%-20%) at 1 year in the URD group and UCB
roup, respectively, P  .055 (Figure 1Bii).
redictors of Mortality
In univariate analysis, progressive onset of
GVHD (P  .0001), platelet count 100,000/L
P .0001), liver involvement (P .0001), and no CR
r PR at 6 months (P  .0001) were each signiﬁcant
redictors of poor survival.
Because of a strong concordance of risk factors
low platelet count and poor response) within the
onor groups, multivariate analysis for survival was
erformed separately in the URD and UCB cohorts.
s shown in Table 6, in the URD cohort, no CR or
R by 2 months (relative risk [RR], 2.5, 95% CI
.1-1.5, P .02), progressive onset of disease (RR 2.7,
5% CI 1.3-6.0, P  .0001), and platelets
100,000/L (RR 4.6, 95% CI 1.7-12.3, P .001)
ere independently signiﬁcant predictors of poor sur-
ival. Similarly in the UCB recipients, no CR or PR at
months (RR 12.5, 95 CI 1.8-87.0, P  .01) and
latelets100,000/L (RR 6.6, 95% CI 1.1-43.4, P
05) were independently signiﬁcant predictors of poor
urvival. Neither intensity of conditioning regimen
or patient age was a signiﬁcant predictor of survival
n either cohort.
uration of Treatment and Outcome
Seventy-seven patients survived 2 years or more
fter diagnosis of cGVHD. Of these, 40 (57%) pa-
ients were still receiving immunosuppression. The
umulative incidence of successful discontinuation of
able 4. Predictors of Early Response (2 Months) (CR or PR)
Predictor OR (CI) P
mbilical cord blood 3.8 (1.3-11.1) .02
e novo or quiescent onset 3.2 (1.1-9.3) .03
ge <30 1.12 (0.4-3.4) .80
yeloablative conditioning 2.6 (0.5-13.4) .96
R indicates complete response; PR, partial response.
hown are the odds ratio (OR) and 95% conﬁdence interval (CI)
favoring response (CR or PR) at 2 months after multivariate
logistic regression.
able 5. Predictors of Late Response (2 Years) (CR or PR)
Predictor OR (CI) P
mbilical cord blood 6.6 (1.9-23.8) .003
e novo or quiescent onset 3.8 (1.1-12.8) .03
ge <30 1.8 (0.6-5.6) .3
yeloablative conditioning 3.4 (0.4-26.1) .3
R indicates complete response; PR, partial response.
hown are the odds ratio (OR) and 95% conﬁdence interval (CI)
favoring response (CR or PR) at 2 years after multivariate
logistic regression.
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M. Arora et al.1150mmunosuppressive treatment was 48% in URD ver-
us 55% in the UCB cohort at 2 years, 63% versus
6% at 3 years, and 77% versus 73% at 4 years, P 
7 (Figure 2).
ISCUSSION
Experience in unrelated UCB transplantation in-
icates that UCB transplantation is associated with a
ower incidence of severe aGVHD and cGVHD de-
pite greater donor:recipient HLA disparity [22,23].
e report our comparative analysis of the outcomes
f patients with cGVHD following URD and UCB
Figure 1. Survival, relapse and non
able 6. Predictors of Mortality
U
Predictor RR (CI)
o CR/ PR at 2 months 2.5 (1.1-5.5)
rogressive onset 2.7 (1.3-6.0)
latelet <100,000/L 4.6 (1.7-12.3)
ge >30 years 1.2 (0.6-2.6)
on myeloablative conditioning 0.8 (0.2-2.4)
R indicates complete response; PR, partial responses (at 2 month
hown is the relative risk (RR) (95% conﬁdence interval, CI) of mo
of a strong concordance of risk factors (low platelet count and p
performed separately in the URD and UCB cohorts.SCT using the uniform clinical management and
upportive care at our center.
We found that UCB grafts were associated with
oth a lower incidence of cGVHD and a higher re-
ponse rate to immunosuppressive therapy compared to
RD HSCT. We noted a lower incidence of cGVHD
n ourURD cohort. However, 33% of these patients had
eceived T cell depletion. Importantly, patients receiving
CB transplant were signiﬁcantly older and more fre-
uently received HLA mismatched grafts. However, be-
ause of the retrospective nature of this study, further
etails about disease characteristics and patient-reported
mprovement in symptoms could not be assessed. Re-
mortality after onset of cGVHD.
UCB
P RR (CI) P
.02 12.5 (1.8-87.0) .01
<.0001 1.03 (0.04-26.1) .9
.001 6.6 (1.0-43.4) .045
.6 0.2 (0.007-1.8) .2
.6 0.3 (0.01-3.8) .3
ation).
ollowing therapy for cGVHD in URD and UCB cohorts. Because
onse) with the donor groups, multivariate analysis for survival wasRD
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cGVHD Following URD and UCB Transplant 1151ponse assessments were based on physician’s assessment
t particular time points. More prospective studies are
equired to deﬁne the disease course and response in
atients undergoing HSCT.
The clinical presentation of cGVHD (organ in-
olvement and time to onset of cGVHD) was similar
n both groups. A higher early response rate in UCB
ecipients was observed, which was sustained at 2 years
fter transplant. Similar to other studies reporting
ostly sibling donor HSCT, de novo or quiescent
nset [18,28] of cGVHD was associated with good
esponse.
cGVHD is one of the most important causes of
RM after transplant. In this study we observed a
ower NRM in UCB transplant recipients. Factors
hat have been associated with higher mortality in
GVHD include “extensive” cGVHD [15-17], poor
arnofsky performance status [19], thrombocytopenia
100,000 cells/L) [15,16,18,19], progressive-type
nset [16,18,20], lichenoid histology [20], elevated bil-
rubin [20], age 20 years [18], gastrointestinal in-
olvement [18], absence of response to therapy at 6
onths [18], and other subjective measures of severity
21]. In this cohort, organ involvement was similar in
oth the groups, and URD transplant recipients were
igniﬁcantly younger than UCB transplant. However,
hrombocytopenia was seen more frequently in URD
ransplant recipients.
A trend toward better survival was also seen in the
CB transplant recipients. Similar to other studies,
hrombocytopenia, progressive onset, and lack of CR
r PR were identiﬁed as signiﬁcant prognostic factors
ssociated with poor survival [16,18,28,29,31] in both
RD and UCB recipients.
Despite higher response rates in the UCB group,
he incidence and timing of discontinuing immuno-
uppression was similar in the 2 cohorts. About half of
he patients still required treatment for2 years, with
early a quarter continuing immunosuppressive ther-
py beyond 4 years. These data are similar to prior
tudies documenting the need for prolonged immu-
igure 2. Cumulative incidence of discontinuation of immuno-
uppression.osuppression in all these patients [18,30,31]. Stewartt al. [30] and Koc et al. [31] reported only 50% of
atients had discontinued therapy after 5-7 years.
In conclusion, in this ﬁrst detailed analysis of out-
omes of patients with cGVHD following UCB and
RD transplants, we found that cGVHD may be less
requent and more responsive after UCBT. NRM is
lso lower after UCB HSCT. Recognition of a high-
isk group (progressive onset, no PR at 2 months, and
latelet count 100,000/L) should facilitate assign-
ent of more intensiﬁed regimens to these patients
fter HSCT from either graft source.
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